EP300 and posterior cortical atrophy: This issue is particularly relevant because p300 inhibitors enter clinical trials in oncology, thus pointing to appropriate selection of patients who will benefit from specific p300 targeting in combinations with other drugs approved or tested for treatment of PCa.